Webinar: Investigating PIM1 in Prostate Cancer with Metabolomics

Investigating PIM1 in Prostate Cancer with Metabolomics

Tuesday, June 4th

12 PM ET | 9 AM PT

Presenter: Noel Warfel, PhD
Hosted by: Panome Bio

Prostate cancer is one of the most common cancers in the world and the 2nd most deadly in men. Castrate resistant prostate cancers (CRPC) have an extremely poor prognosis and currently no known treatments. In this webinar, Dr. Warfel dives into a study surrounding lipid droplet (LD) accumulation in solid tumors. In the study, PIM1 kinase was discovered to have an influence on LD accumulation by modulating the activity of glycogen synthase kinase 2 beta (GSK3β) and stabilizing peroxisome proliferator-activated receptor α (PPARα). This multi-omic study included the utilization of Next-Generation Metabolomics from Panome Bio to understand tumor metabolism in CRPC.

Noel Warfel, PhD, received his B.S. in 2004 from James Madison University, with a dual concentration in Engineering and Biotechnology. Following undergrad, he was awarded the Molecular Targets and Drug Discovery Fellowship, a joint program sponsored by Johns Hopkins University and the NIH, where he earned an M.S. in Biotechnology. During this time, he trained at the NCI in the lab of Dr. Phil Dennis studying PI3K signaling in lung cancer. Noel received his Ph.D. in Biomedical Sciences in 2011 from UC San Diego in the lab of Dr. Alexandra Newton, where he studied mechanisms responsible for Akt activation in cancer. His postdoctoral research was conducted as a NCI Ruth L. Kirschstein postdoctoral fellow at the Penn State Hershey Cancer Center in the lab of Dr. Wafik El-Deiry. There, he gained experience in translational medicine studying novel mechanisms of HIF-1 regulation. In 2015, Noel joined the Department of Cellular and Molecular Medicine at the University of Arizona as an Assistant Professor. He is also a member of the UA cancer center and is funded by the American Cancer Society and Department of Defense PCRP.

Register Now

Your privacy is important to us.
We'll never share your information.

Skip to content